Furthermore, the dosing of small-molecule tyrosine kinase inhibitors typically involves administering several oral tablets daily, which can pose additional challenges in ensuring patient compliance in the effective management of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.